In recent years, significant progress has been made in direct-targeting agents targeting KRAS, with the KRAS (G12C) inhibitors sotorasib and adagrasib achieving initial success in NSCLC and regulatory approval for both drugs [122, 123]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.